We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Comparative study of Revogene GBS LB assay and GeneXpert GBS LB assay for the detection of group B Streptococcus in prenatal screening samples.
- Authors
Choera, Tsokyi; Jung-Hynes, Brittney; Chen, Derrick J.
- Abstract
<bold>Background: </bold>Group B Streptococcal (GBS) infections in the United States are a leading cause of meningitis and sepsis in newborns. The CDC therefore recommends GBS screening for all pregnant women at 35-37 weeks of gestation and administration of intrapartum prophylaxis (in those that tested positive) as an effective means of controlling disease transmission. Several FDA approved molecular diagnostic tests are available for rapid and accurate detection of GBS in antepartum women.<bold>Method: </bold>In this study, we report a clinical comparison of the Xpert GBS LB assay and a novel FDA-cleared test, Revogene GBS LB assay. A total of 250 vaginal-rectal swabs from women undergoing prenatal screening were submitted to the University of Wisconsin's clinical microbiology laboratory for GBS testing.<bold>Results: </bold>We found 96.8% of samples were concordant between the two tests, while 3.2% were discordant with a positive percent agreement of 98.0% and a negative percent agreement of 96.5% between the Revogene GBS LB assay and the GeneXpert GBS LB assay.<bold>Conclusion: </bold>Overall, we report that both assays perform well for the detection of GBS colonization in pregnant women.
- Subjects
UNITED States. Food &; Drug Administration; STREPTOCOCCUS agalactiae; UNIVERSITY of Wisconsin; MEDICAL microbiology; NUCLEIC acid amplification techniques
- Publication
BMC Infectious Diseases, 2020, Vol 20, Issue 1, p1
- ISSN
1471-2334
- Publication type
journal article
- DOI
10.1186/s12879-019-4756-y